TY - JOUR
T1 - Novel therapies are changing treatment paradigms in metastatic prostate cancer
AU - Powers, Eric
AU - Karachaliou, Georgia Sofia
AU - Kao, Chester
AU - Harrison, Michael R.
AU - Hoimes, Christopher J.
AU - George, Daniel J.
AU - Armstrong, Andrew J.
AU - Zhang, Tian
N1 - Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors for patients with mCRPC and mutations in DNA damage repair genes has added to the treatment armamentarium and improved personalized treatments for prostate cancer. Other promising therapeutic agents currently in clinical development include the radiotherapeutic 177-lutetium-prostate-specific membrane antigen (PSMA)-617 targeting PSMA-expressing prostate cancer and combinations of immunotherapy with currently effective treatment options for prostate cancer. Herein, we have highlighted the progress in systemic treatments for mCRPC and the promising agents currently in ongoing clinical trials.
AB - Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors for patients with mCRPC and mutations in DNA damage repair genes has added to the treatment armamentarium and improved personalized treatments for prostate cancer. Other promising therapeutic agents currently in clinical development include the radiotherapeutic 177-lutetium-prostate-specific membrane antigen (PSMA)-617 targeting PSMA-expressing prostate cancer and combinations of immunotherapy with currently effective treatment options for prostate cancer. Herein, we have highlighted the progress in systemic treatments for mCRPC and the promising agents currently in ongoing clinical trials.
KW - Androgen receptor inhibitors (ARIs)
KW - Castration-resistant prostate cancer
KW - Metastatic prostate cancer
KW - Polyadenosine diphosphate [ADP]-ribose polymerase (PARP) inhibitor
KW - Prostate-specific membrane antigen (PSMA)
UR - http://www.scopus.com/inward/record.url?scp=85094174977&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094174977&partnerID=8YFLogxK
U2 - 10.1186/s13045-020-00978-z
DO - 10.1186/s13045-020-00978-z
M3 - Review article
C2 - 33115529
AN - SCOPUS:85094174977
SN - 1756-8722
VL - 13
JO - Journal of Hematology and Oncology
JF - Journal of Hematology and Oncology
IS - 1
M1 - 144
ER -